{"id":"sumatriptan-succinate-naproxen-sodium","safety":{"commonSideEffects":[{"rate":null,"effect":"Chest pain or pressure"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Paresthesia"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Flushing"}]},"_chembl":{"chemblId":"CHEMBL1201150","moleculeType":"Small molecule","molecularWeight":"413.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sumatriptan selectively activates serotonin 5-HT1B and 5-HT1D receptors on cranial blood vessels and trigeminal nerve terminals, causing vasoconstriction and reducing the release of inflammatory neuropeptides involved in migraine pathophysiology. Naproxen sodium inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin production and providing additional anti-inflammatory and analgesic effects. The combination targets both the vascular and inflammatory components of migraine.","oneSentence":"Sumatriptan is a 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release, while naproxen is an NSAID that inhibits prostaglandin synthesis to reduce inflammation and pain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:14.995Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute migraine with or without aura"}]},"trialDetails":[{"nctId":"NCT04948164","phase":"PHASE3","title":"Study of Sumatriptan Naproxen Sodium Succinate Tablets for the Treatment of Acute Migraine Attacks","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2018-08-01","conditions":"Migraine in Adults","enrollment":240},{"nctId":"NCT00385008","phase":"PHASE3","title":"TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-13","conditions":"Migraine Disorders","enrollment":20},{"nctId":"NCT00875784","phase":"PHASE1","title":"An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05-06","conditions":"Migraine Disorders","enrollment":30},{"nctId":"NCT00488514","phase":"PHASE3","title":"Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-13","conditions":"Migraine Disorders","enrollment":656},{"nctId":"NCT00383162","phase":"PHASE3","title":"A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11","conditions":"Migraine Disorders","enrollment":173},{"nctId":"NCT00382993","phase":"PHASE3","title":"A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12","conditions":"Migraine Disorders","enrollment":169},{"nctId":"NCT00329355","phase":"PHASE3","title":"Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"Migraine, Migraine Disorders","enrollment":351},{"nctId":"NCT00843024","phase":"PHASE3","title":"Migraine Study in Adolescent Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Migraine Disorders","enrollment":589},{"nctId":"NCT00387881","phase":"PHASE3","title":"TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09","conditions":"Migraine, Without Aura","enrollment":679},{"nctId":"NCT00240617","phase":"PHASE3","title":"Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10","conditions":"Migraine Disorders","enrollment":623},{"nctId":"NCT00329459","phase":"PHASE3","title":"Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"Migraine Disorders","enrollment":320},{"nctId":"NCT00240630","phase":"PHASE3","title":"Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10","conditions":"Migraine Disorders, Migraine","enrollment":646},{"nctId":"NCT00893737","phase":"PHASE4","title":"\"Completeness of Response\" Following Treatment With Treximet™ for Migraine","status":"COMPLETED","sponsor":"Cady, Roger, M.D.","startDate":"2009-06","conditions":"Migraine","enrollment":147},{"nctId":"NCT00573170","phase":"PHASE3","title":"TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02","conditions":"Migraine Disorders, Migraine, Acute","enrollment":375},{"nctId":"NCT00837044","phase":"NA","title":"Treximet in Acute Migraine Headache: Assessing Cognitive Function","status":"UNKNOWN","sponsor":"Neurological Research Center","startDate":"2009-02","conditions":"Migraine Headache, Cognitive Impairment","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"DRUG INEFFECTIVE"},{"count":3,"reaction":"NAUSEA"},{"count":2,"reaction":"HEADACHE"},{"count":2,"reaction":"PSEUDOPORPHYRIA"},{"count":2,"reaction":"VOMITING"},{"count":1,"reaction":"ANGINA BULLOSA HAEMORRHAGICA"},{"count":1,"reaction":"BLOOD BILIRUBIN INCREASED"},{"count":1,"reaction":"COLITIS MICROSCOPIC"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"DYSGEUSIA"}],"_approvalHistory":[],"publicationCount":70,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Treximet","Treximet (TM)"],"phase":"marketed","status":"active","brandName":"sumatriptan succinate/naproxen sodium","genericName":"sumatriptan succinate/naproxen sodium","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sumatriptan is a 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release, while naproxen is an NSAID that inhibits prostaglandin synthesis to reduce inflammation and pain. Used for Acute migraine with or without aura.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}